Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +36.67% and -53.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?